Efavirenz

Contraindicated

Efavirenz Maraviroc Selzentry Decreased maraviroc plasma concentrations and exposure (AUC) Details

Major

Efavirenz Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Efavirenz Abametapir Explained Increased exposure of CYP3A4 substrate Details Efavirenz Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Efavirenz Sertraline Explained Reduced sertraline exposure and an increased risk of QT interval prolongation Details Efavirenz Buprenorphine Belbuca Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Efavirenz Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Efavirenz Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Efavirenz Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Efavirenz Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Efavirenz Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Efavirenz Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Efavirenz Atogepant Qulipta Reduced atogepant exposure Details Efavirenz Atovaquone Mepron Reduced atovaquone exposure Details Efavirenz Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Efavirenz Azathioprine Azasan An increased risk of hepatotoxicity Details Efavirenz Azithromycin AzaSite An increased risk of QT interval prolongation Details Efavirenz Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Efavirenz Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Efavirenz Alfuzosin UroXatral An increased risk of QT interval prolongation Details Efavirenz Anagrelide Agrylin An increased risk of QT interval prolongation Details Efavirenz Avanafil Stendra Decreased avanafil plasma concentrations Details Efavirenz Axitinib Inlyta Reduced axitinib exposure Details Efavirenz Bedaquiline Sirturo Reduced bedaquiline exposure and an increased risk of QT interval prolongation Details Efavirenz Bexarotene Targretin Reduced efavirenz exposure with reduced efficacy; reduced bexarotene exposure with reduced efficacy Details Efavirenz Bexarotene Topical Targretin Reduced efavirenz exposure with reduced efficacy; reduced bexarotene exposure with reduced efficacy Details Efavirenz Brigatinib Alunbrig Decreased brigatinib exposure and efficacy Details Efavirenz Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Efavirenz Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Efavirenz Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Efavirenz Capmatinib Tabrecta Decreased capmatinib exposure and reduction of antitumor activity Details Efavirenz Chloroquine Aralen® An increased risk of QT interval prolongation Details Efavirenz Cobimetinib Cotellic Decreased cobimetinib plasma concentrations Details Efavirenz Cyclosporine Injection Atopica Reduced cycloSPORINE exposure Details Efavirenz Cyclosporine Ophthalmic Cequa Reduced cycloSPORINE exposure Details Efavirenz Dabigatran Pradaxa® Reduced dabigatran exposure, reduced efficacy of dabigatran and an increased risk of thrombosis Details Efavirenz Dabigatran Etexilate Reduced dabigatran exposure, reduced efficacy of dabigatran and an increased risk of thrombosis Details Efavirenz Dasatinib Phyrago An increased risk of QT interval prolongation Details Efavirenz Deflazacort Emflaza Decreased exposure to active metabolite of deflazacort Details Efavirenz Degarelix Injection Firmagon Increased risk of QT interval prolongation Details